Sintilimab + Cisplatin + Paclitaxel + Fluorouracil + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Esophageal Squamous Cell Carcinoma
Conditions
Esophageal Squamous Cell Carcinoma
Trial Timeline
Dec 24, 2018 → Jul 29, 2023
NCT ID
NCT03748134About Sintilimab + Cisplatin + Paclitaxel + Fluorouracil + Placebo
Sintilimab + Cisplatin + Paclitaxel + Fluorouracil + Placebo is a phase 3 stage product being developed by Innovent Biologics for Esophageal Squamous Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03748134. Target conditions include Esophageal Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03748134 | Phase 3 | Completed |
Competing Products
20 competing products in Esophageal Squamous Cell Carcinoma